Comerica Bank Has $5.29 Million Stake in Maximus, Inc. $MMS

Comerica Bank lifted its stake in shares of Maximus, Inc. (NYSE:MMS) by 124.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 61,284 shares of the health services provider’s stock after buying an additional 33,973 shares during the period. Comerica Bank’s holdings in Maximus were worth $5,290,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of MMS. Boston Partners grew its position in shares of Maximus by 47.0% during the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock worth $88,236,000 after buying an additional 308,892 shares during the period. UBS Group AG grew its position in shares of Maximus by 76.8% during the 4th quarter. UBS Group AG now owns 610,354 shares of the health services provider’s stock worth $52,686,000 after buying an additional 265,095 shares during the period. Stephens Investment Management Group LLC grew its position in shares of Maximus by 49.0% during the 3rd quarter. Stephens Investment Management Group LLC now owns 720,943 shares of the health services provider’s stock worth $65,873,000 after buying an additional 237,097 shares during the period. Qube Research & Technologies Ltd grew its position in shares of Maximus by 115.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 379,342 shares of the health services provider’s stock worth $26,630,000 after buying an additional 203,521 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Maximus during the 4th quarter worth approximately $15,673,000. Institutional investors and hedge funds own 97.21% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on MMS shares. Weiss Ratings downgraded shares of Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research report on Tuesday, February 24th. Zacks Research downgraded shares of Maximus from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Wall Street Zen downgraded shares of Maximus from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Maximus has a consensus rating of “Hold”.

Insider Buying and Selling

In related news, CEO Bruce Caswell purchased 3,175 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was acquired at an average cost of $78.45 per share, with a total value of $249,078.75. Following the transaction, the chief executive officer owned 328,013 shares of the company’s stock, valued at $25,732,619.85. This represents a 0.98% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jan Madsen sold 742 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $72.25, for a total value of $53,609.50. Following the completion of the sale, the director directly owned 20,795 shares of the company’s stock, valued at $1,502,438.75. The trade was a 3.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.80% of the stock is owned by company insiders.

Maximus Price Performance

Shares of MMS opened at $65.55 on Friday. Maximus, Inc. has a 12-month low of $60.75 and a 12-month high of $100.00. The business’s fifty day moving average is $69.28 and its 200 day moving average is $80.47. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.88. The stock has a market cap of $3.58 billion, a P/E ratio of 9.98 and a beta of 0.60.

Maximus (NYSE:MMS) last issued its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.01. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.37 billion. During the same period last year, the business earned $1.61 EPS. Maximus’s quarterly revenue was down 4.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. Sell-side analysts anticipate that Maximus, Inc. will post 8.46 earnings per share for the current fiscal year.

Maximus Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be issued a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Friday, May 15th. Maximus’s dividend payout ratio (DPR) is currently 20.09%.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.